Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(14 sites)
United States
UCLA Hematology/Oncology, Los Angeles, California Sarah Cannon Research Institute (SCRI), Denver, Colorado Yale Cancer Center, New Haven, Connecticut Florida Cancer Specialists, Sarasota, Florida Moffitt Cancer Center, Tampa, Florida